Lynette Keyes-Elstein

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

Keith Sullivan, Ellen Goldmuntz, Lynette Keyes-Elstein et al. · New England Journal of Medicine · 2018 · 589 citations · Full text

Medicine, Hematology, Immunology +13

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers et al. · Diabetes · 2013 · 405 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

Mark Rigby, Kristina M. Harris, Ashley Pinckney et al. · Journal of Clinical Investigation · 2015 · 292 citations · Full text

Medicine, Endocrinology, Immunology +17

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

Mark Rigby, Linda A. DiMeglio, Marc Rendell et al. · The Lancet Diabetes & Endocrinology · 2013 · 206 citations · Full text

Life Sciences, Endocrinology, Immunology +17

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

Elizabeth R. Volkmann, Donald P. Tashkin, Myung‐Shin Sim et al. · Annals of the Rheumatic Diseases · 2018 · 198 citations

Public Health, Biostatistics, Pharmacotherapy +13